Patent ID: 8735558

Claim:
A method for modulating the secretion, expression or synthesis of adhesion proteins or angiopoietin in cells, comprising contacting said cells with an effective amount of an isolated, purified or synthesized compound, or its salt or ester thereof, selected from the formula: wherein R 1 is selected from hydrogen, hydroxyl, O-alkanoyl, O-alkenoyl and O-sugar moiety, wherein the sugar moiety is attached with two groups selected from alkanoyl and alkenoyl; R 2 is selected from hydrogen, hydroxyl, alkanoyl, O-alkenoyl and O-acyl; R 4 is selected from CH 2 R 6 , wherein R 6 is a group selected from hydroxyl, O-angeloyl, O-tigloyl, O-senecioyl, O-alkanoyl, O-alkenoyl and O-acyl; wherein at least two of R 1 , R 2 and R 6 are a group having an alkanoyl, alkenoyl, acyl, or any of R 1 , R 2 and R 6 has a sugar moiety having two alkanoyl, alkenoyl, acyl; wherein the acyl groups are selected from angeloyl, tigloyl, senecioyl, methylpropanoyl, methylbutanoyl and acetyl; wherein the alkanoyl is methylpropanoyl, acetyl or methylbutanoyl; wherein the alkenoyl is angeloyl, tigloyl or senecioyl; R 3 is H or OH; R8 is H or OH; R 5 is a hydrogen or sugar moiety(ies), wherein the sugar moiety(ies) is/are selected from a group consisting of glucose, galactose, rhamnose, arabinose, xylose, fucose, allose, altrose, gulose, idose, lyxose, mannose, psicose, ribose, sorbose, tagatose, talose, fructose, alduronic acid, glucuronic acid, galacturonic acid, and derivatives or combination thereof; wherein R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 of the compound is independently attached with a group selected from CH 3 , CH 2 OH, CHO, COOH, COO-alkyl, COO-aryl, COO-heterocyclic, COO-heteroaryl, CH 2 Oaryl, CH 2 O-heterocyclic, CH 2 O-heteroaryl, alkyls, hydroxyl and acetyl group; wherein drug concentration is not over 10 ug/ml; wherein the secretion of adhesion proteins is determined by a method comprising the following steps: 1. Growing cells in RPMI 1640 medium over night before drug-treatment; 2. Replacing cells cultures with fresh RPMI medium containing selected compound (1, 5, or 10 ug/ml concentration) or DMSO (as control) at 0 hour; 3. Replacing with fresh culture medium without drug at 4 hours (A) or 8 hours (B); 4. Determining adhesion proteins in aliquot of culture medium at 2, 4, 8 and 24 hour; 5. Determining adhesion proteins by Western blot with monoclonal antibody specific only to human adhesion proteins; 6. Comparing the adhesion proteins in control and drug-treated cells before drug removal at 4 and 8 hours; 7. Checking cells morphology at all times to make sure cells are alive; 8. Comparing the reduction of adhesion proteins in treated cells (compare to control cells) at 4, 8 and 24 hours; and 9. Comparing the amount of adhesion proteins secreted by treated cells at 24 hours (including those have 4 and 8 hours of drug-treatments), wherein the secretion continues after removal of drug, indicating that the cells are alive after drug treatment and capable of secreting adhesion proteins.